학술논문
A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology
Document Type
Article
Author
Source
In ESMO Open October 2023 8(5)
Subject
Language
ISSN
2059-7029